Medicenna Therapeutics (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, has announced the completion of a CA$20 million investment from RA Capital Management through a private placement. The funds will propel the development of Medicenna’s MDNA11 program and other preclinical initiatives. Despite the investment, the securities involved in the transaction have not been registered under the U.S. Securities Act and are subject to certain restrictions on sale and offer.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
